Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.

Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical ...

Life science tools and diagnostics provider Bio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to GMP grade small molecules.

Genomics has entered into a multi-project research agreement with Fred Hutch for advancing single cell as well as spatial platforms in solid tumours and blood cancers.

The latest trends emerging from the European Association for the Study of Diabetes (EASD) 2026 meeting forecast a competitive space for diabetes treatments in the years to come. Image credit: ...

The US FDA has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.

The US FDA has approved an expanded indication for Lilly's Jaypirca as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.

Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.

AstraZeneca has opened a new global strategic R&D facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.